Yuanhui Sun

Ms. Yuanhui Sun

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in BMC Nursing
Verified
Journal Article
Open access
PDF file
ZYZhen Yang
Zhen Yang
YSYuanhui Sun
Yuanhui Sun
HWHuan Wang
Huan Wang
CZChunqi Zhang
Chunqi Zhang
AWAiping Wang
Aiping Wang
Background: The benefits of home-based cardiac rehabilitation exercise are well-established and depend on long-term adherence. However, there is no uniform and recognized cardiac rehabilitation criterion to assess home-based cardiac rehabilitation exercise adherence for patients with cardiovascular disease. This study aimed to develop a home-based cardiac rehabilitation exercise adherence scale and to validate its psychometric properties among patients with chronic heart failure. Methods: The dimensions and items of the scale were created based on grounded theory research, literature content analysis, and defined by a Delphi survey. Item analysis was completed to assess the discrimination and homogeneity of the scale. Factor analysis was adopted to explore and validate the underlying factor structure of the scale. Content validity and calibration validity were evaluated using the Delphi survey and correlation analysis, respectively. Reliability was evaluated by Cronbach’s α coefficients, split-half reliability coefficients, and test-retest reliability coefficients. Results: A scale covering four dimensions and 20 items was developed for evaluating home-based cardiac rehabilitation exercise adherence. The content validity index of the scale was 0.986. In exploratory factor analysis, a four-factor structure model was confirmed, explaining 75.1% of the total variation. In confirmatory factor analysis, the four-factor structure was supported by the appropriate fitting indexes. Calibration validity of the scale was 0.726. In terms of reliability, the Cronbach’s α coefficient of the scale was 0.894, and the Cronbach’s α coefficients of dimensions ranged from 0.848 to 0.914. The split-half reliability coefficient of the scale was 0.695. The test-retest reliability coefficient of the scale was 0.745. Conclusion: In this study, a home-based cardiac rehabilitation exercise adherence scale was developed and its appropriate psychometric properties were confirmed.

26 August 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
YSYuanhui Sun
Yuanhui Sun
SMSiyu Mu
Siyu Mu
Objective: Selective serotonin reuptake inhibitors (SSRIs) are recognized for their antidepressant effects and their potential role in promoting neuroplasticity. This systematic review and meta-analysis aimed to evaluate whether SSRIs improve prognostic outcomes in patients with stroke compared with placebo or no intervention. Methods: We systematically searched the Cochrane Library, PubMed, and Embase databases to identify randomized controlled trials comparing SSRIs with placebo or no intervention in patients with stroke. Continuous outcomes were pooled using weighted mean differences (WMDs), and dichotomous outcomes were pooled using risk ratios (RRs), both with 95% confidence intervals (CIs). Fixed-effect or random-effects models were selected according to the degree of statistical heterogeneity for each outcome. Results: Eleven reports from nine unique randomized controlled trials, involving 7,604 unique participants, were included. In exploratory analyses stratified by follow-up duration, SSRI use at 3 months was associated with better modified Rankin Scale (mRS) responder status and a greater absolute reduction in National Institutes of Health Stroke Scale score (absNIHSS) (RR 2.46, 95% CI 1.74–3.48; WMD 0.57, 95% CI 0.11–1.03). However, the 3-month mRS finding was derived from a single trial and should therefore be interpreted with particular caution. At 6 months, SSRI use was associated with a smaller absolute reduction in NIHSS score (WMD −0.23, 95% CI–0.45 to −0.02), but this finding should also be interpreted cautiously because the absNIHSS analysis showed substantial heterogeneity. At 12 months, SSRI use was associated with a lower risk of recurrent stroke (RR 0.65, 95% CI 0.47–0.89), particularly recurrent ischemic stroke (RR 0.57, 95% CI 0.40–0.80). These findings suggest that the observed associations between SSRI use and stroke outcomes varied across follow-up-duration subgroups. However, these subgroup patterns should be interpreted cautiously because they may reflect differences in study populations, follow-up designs, attrition, rehabilitation strategies, and trial weighting rather than a confirmed biological time-dependent effect. No statistically significant differences were observed in thrombotic events, bleeding events, mortality, cardiac adverse events, or drug-specific subgroup analyses. Conclusion: SSRI use after stroke may be associated with selected exploratory short-term functional signals and a lower long-term risk of recurrent stroke, particularly recurrent ischemic stroke. However, the apparent short-term mRS benefit was driven by a single trial and should not be interpreted as a robust or generalizable clinical effect. The mid-term absNIHSS findings did not support a sustained functional benefit and were accompanied by substantial heterogeneity. Therefore, the functional outcome findings should be interpreted as exploratory rather than definitive. The observed associations should be interpreted cautiously because they were derived from exploratory follow-up-duration-stratified analyses and represent subgroup-level associations rather than evidence of a causal temporal or biological effect of SSRIs. Further well-designed randomized controlled trials are needed to clarify the optimal timing, duration, and safety of SSRI therapy after stroke.